Time filter

Source Type

Dublin, Ireland

Agency: Cordis | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2014 | Award Amount: 234.00K | Year: 2015

The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to develop a platform of green chemoenzymatic methods for the production of high value active pharmaceutical ingredients both those currently on the market, and those in development pipelines of the Pharma industry. The partners will exemplify the use of the platform through its application in the production of 4 drugs currently on the market namely Duloxetine, Atomexetine, Ramosetron and Paricalcitol. In order to achieve this objective the proposal brings together 3 partners with complementary skills: Kelada Pharmachem: Phase transfer catalysis/organo catalysis/scale-up of chemical processes Cerbios Pharma: Biocatalysis and fermentation methodologies for drug production IC-CNR: Protein crystallography and enzymatic engineering.

KelAda Pharmachem | Entity website

Currently Available Licenses KelAda Pharmachem is actively seeking licensees to our proprietary manufacturing process for Pregabalin. The key features of the process are as follows: Estimated cost of materials (ton scale) ca ...

KelAda Pharmachem | Entity website

Currently AvailableProductsWe leverage our proprietary technology and processes to offer a range of niche products for usein the synthesis ofdrugs currentlyin clinical development or for use as medicinal chemistry templates.Click here to view our catalogue of productsPlease contact us for orders and enquiries

KelAda Pharmachem | Entity website

ServicesOur services are centred on the provision of contract synthesis and process development. In particular wefocus upon reducing costs of production by avoiding expensive transition metals thus impacting economics and long term sustainability ...

KelAda Pharmachem | Entity website

KelAda Pharmachem was established in Ireland to acquire and develop intellectual assets in the pharmachemical space. The companys model is to in-license and develop novel chemistry into scalable processes which can then be out-licensed to major pharmaceutical players ...

Discover hidden collaborations